Cytokinetics Ownership | Who Owns Cytokinetics?
Cytokinetics Ownership Summary
Cytokinetics is owned by 13.64% institutional investors, 0.77% insiders, and 85.60% retail investors. Blackrock is the largest institutional shareholder, holding 14.40% of CYTK shares. Vanguard Health Care Inv is the top mutual fund, with 3.41% of its assets in Cytokinetics shares.
CYTK Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Cytokinetics | 13.64% | 0.77% | 85.60% |
Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Blackrock | 14.67M | 14.40% | $794.97M |
Blackrock funding, inc. /de | 15.47M | 13.14% | $727.68M |
Vanguard group | 11.92M | 10.13% | $560.52M |
Fmr | 10.79M | 9.17% | $507.78M |
T. rowe price investment management | 10.75M | 9.14% | $505.78M |
Wellington management group llp | 7.89M | 6.70% | $371.08M |
State street | 6.17M | 5.24% | $290.11M |
Deep track capital, lp | 3.07M | 2.59% | $123.54M |
Geode capital management | 2.84M | 2.41% | $133.69M |
Rtw investments, lp | 2.72M | 2.30% | $109.36M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Rp management | 980.39K | 22.73% | $51.76M |
Sarissa capital management lp | 833.80K | 12.15% | $39.22M |
Great point partners | 370.00K | 7.88% | $14.87M |
Vestal point capital, lp | 2.59M | 7.43% | $104.11M |
Boxer capital | 2.10M | 5.99% | $113.78M |
Superstring capital management lp | 129.39K | 5.27% | $6.09M |
Melqart asset management (uk) | 999.45K | 5.24% | $40.17M |
Dafna capital management | 398.10K | 4.54% | $16.00M |
Allostery investments lp | 70.00K | 4.06% | $2.81M |
Integral health asset management | 1.00M | 4.01% | $47.04M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Blackrock | 14.67M | 0.02% | 2.26M |
Capital investors | 1.10M | 0.01% | 1.10M |
T. rowe price investment management | 10.75M | 0.31% | 1.06M |
Norges bank | 989.72K | 0.01% | 989.72K |
Ubs group | 1.20M | 0.01% | 888.44K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Darwin global management | - | - | -4.58M |
Pfm health sciences, lp | - | - | -1.76M |
Westfield capital management co lp | - | - | -1.31M |
Fmr | 10.79M | 0.03% | -1.30M |
Hood river capital management | - | - | -1.26M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Capital investors | 1.10M | 0.01% | 1.10M | $51.56M |
Norges bank | 989.72K | 0.01% | 989.72K | $46.56M |
Paradigm biocapital advisors lp | 858.66K | 1.58% | 858.66K | $34.51M |
Groupama asset managment | 350.00K | 0.01% | 350.00K | $421.29K |
Cutter capital management, lp | 175.00K | 3.06% | 175.00K | $7.03M |
Sold Out
Holder | Change |
---|---|
True wealth design | -1.00 |
New england capital financial advisors | -1.00 |
Financial gravity asset management | -2.00 |
Financial management professionals | -5.00 |
American capital advisory | -5.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2025 | 25 | -93.40% | 16,158,180 | -87.73% | 13 | 0.11% | 15 | -91.28% | 5 | -96.09% |
Dec 31, 2024 | 374 | -5.32% | 131,318,059 | -2.91% | 111 | 0.84% | 166 | -12.17% | 128 | 29.29% |
Sep 30, 2024 | 390 | 0.52% | 135,010,879 | -0.29% | 114 | 0.65% | 187 | -6.50% | 99 | -2.94% |
Jun 30, 2024 | 388 | -14.35% | 135,400,422 | 16.07% | 132 | 1.01% | 200 | -11.11% | 102 | -22.14% |
Mar 31, 2024 | 453 | 6.34% | 116,652,886 | 2.18% | 114 | 0.82% | 225 | 10.29% | 131 | 11.02% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Health Care Inv | 4.07M | 3.41% | - |
iShares Core S&P Mid-Cap ETF | 3.89M | 3.25% | -6.99K |
Vanguard Total Stock Mkt Idx Inv | 3.80M | 3.18% | 16.51K |
Vanguard US Total Market Shares ETF | 3.75M | 3.15% | 128.42K |
Vanguard Small Cap Index | 2.92M | 2.44% | -58.37K |
iShares Russell 2000 ETF | 2.75M | 2.30% | -52.19K |
T. Rowe Price Capital Appreciation | 2.44M | 2.04% | 41.02K |
T. Rowe Price Mid-Cap Growth | 2.25M | 1.88% | 268.00K |
T. Rowe Price US Mid-Cap Growth Equity | 2.25M | 1.88% | 267.30K |
T. Rowe Price Small-Cap Value | 2.10M | 1.76% | 288.91K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Aug 05, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | $72.68K |
Jul 29, 2025 | Blum Robert I | President & CEO | Sell | $182.25K |
Jul 22, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | $74.94K |
Jul 14, 2025 | Blum Robert I | President & CEO | Sell | $190.75K |
Jul 08, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | $67.52K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q3 | - | 6 |
2025 Q2 | - | 19 |
2025 Q1 | - | 22 |
2024 Q4 | - | 20 |
2024 Q3 | - | 25 |
CYTK Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools